HiberGene Diagnostics, a portfolio Company of the Bank of Ireland Kernel Capital Funds has been awarded a CE mark for a new rapid COVID-19 test which is now available for sale internationally.This announcement follows the completion of a clinical trial at the Mater Private Hospital. The low cost test deliver results within 60 minutes with a positive result within 30 minutes enabling rapid diagnosis of the disease at the early and highly infectious stage of infection.
Further collaborations to evaluate potential additional uses of the test are planned including clinical evaluations at a hospital in Genoa, Queens University Belfast and at laboratories in China. The project is supported by €1M Horizon 2020 Funding.
“The COVID-19 pandemic is the greatest challenge to humanity in our lifetimes. HiberGene has responded to this global challenge by leveraging our proprietary technology to accelerate the development of an accurate and reliable test for COVID-19. The test is suitable for both decentralised facilities requiring rapid molecular tests for screening and centralised labs requiring additional tests for confirmation or out of hours testing.”
Seamus Gorman, CEO, HiberGene
“I would like to congratulate HiberGene – an Irish based company which is answering the call and stepping up to the plate in our national and global effort to defeat COVID-19. Their hallmark as a company is innovation and adaptability, and the awarding of the CE mark to their COVID-19 diagnostic device to facilitate rapid testing is testament to that. I would like to commend them on their wonderful achievement and wish them every success as they bring the product to market and help Ireland and indeed the world to deal effectively with COVID-19.”
Minister for Business, Enterprise and Innovation, Heather Humphrey’s TD
“I applaud the many Irish companies that are innovating in response to the COVID-19 pandemic and it is exciting to see HiberGene, who are at the forefront of innovation in the delivery of molecular testing for human infectious diseases, use its technology to develop this diagnostic device, which will help address the urgent global demand for testing with fast results. I wish HiberGene success with the development of this new product and we at Enterprise Ireland look forward to continuing to work with the company and other Irish businesses, as they develop new and innovative solutions in response to the crisis.”
Julie Sinnamon, CEO, Enterprise Ireland
“This is a great example of EU research in action. I am encouraged to see that these researchers have risen to the challenge, developed this new diagnostic system so fast, and delivered on one of the aims of our first emergency call. It’s crucial to diagnose coronavirus more quickly and more accurately, as it reduces the risk of further spread of the virus.”
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, European Commission
# # #
For further information please contact:
Dawn Walsh, Kernel Capital
Tel: +353 87 122 6807